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Abstract
Background: The fibrosis-4 index (FIB-4) has been reported to be associated with all-cause mortality in several
chronic diseases. In this study, we investigated whether at diagnosis could be associated with all-cause mortality in
patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).
Methods: We retrospectively reviewed the medical records of 132 MPA and GPA patients without chronic liver
diseases. Conventional risk factors included old age (≥ 65 years), male gender, diabetes mellitus (DM) and
hypertension (HTN) at diagnosis, and disease-related risk factor included GPA, antineutrophil cytoplasmic antibody,
Birmingham vasculitis activity score (BVAS) and five factor score (FFS (2009)). The cut-off of FIB-4 for significant liver
fibrosis (S2–4) was set at 1.45.
Results: The mean age was 57.2 years and 27 patients (20.5%) had significant liver fibrosis (FIB-4 ≥ 1.45). Fifteen
patients (11.4%) died during follow-up. In the univariable Cox Hazards model, age ≥ 65 years (Hazard ratio (HR)
5.055), DM (HR 3.446), HTN (HR 4.611), FFS (2009) ≥ 2 (HR 4.849) and FIB-4 ≥ 1.45 (HR 9.958) at diagnosis were
significantly associated with all-cause mortality. In the multivariable Cox Hazards model, only FIB-4 at diagnosis
≥1.45 (HR 6.253, 95% confidence interval 1.398, 27.963) was associated with all-cause mortality during the follow-up
in patients with MPA and GPA.
Conclusions: FIB-4 at diagnosis ≥1.45 is an independent predictor of all-cause mortality during follow-up in
patients with MPA and GPA, and furthermore its predictive potential is higher than those of conventional and
AAV-related risk factors for all-cause mortality.
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Background
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a group systemic vasculitides, which
can affect small vessels ranging from capillaries to
intraparenchymal arterioles and venules of almost all the
organs [1]. AAV consists of three variants, such as
microscopic polyangiitis (MPA), granulomatosis with
polyangiitis (GPA) and eosinophilic granulomatosis with
polyangiitis (EGPA) [1, 2]. MPA and GPA mainly present
similar pulmonary and renal symptoms despite differ-
ent genetic and antigenic backgrounds, whereas EGPA
often exhibit both allergic and necrotising vasculitic
features [1–3].
Since AAV can bring out an amount of inflammatory
burden and damage in major organs including lungs,
kidneys and heart, AAV can be occasionally fatal. So far,
there have been diverse reports regarding all-cause
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mortality in patients with AAV from different ethnic and
geographic backgrounds: one year-cumulative patient
survival rates were from 82 to 95% in Western countries
[4], and that was reported to be 79.1% in Japan [5]. In
Korean patients with AAV, 10-year cumulative patient
survival rate was estimated up to 92.8% [6].
Renal and pulmonary involvements and five factor
score (FFS (2009)) ≥ 2 at diagnosis of AAV have been re-
ported as AAV-related risk factors for all-cause mortality
[6, 7], together with conventional risk factors for all-
cause mortality among the general population including
age, male gender, diabetes mellitus (DM) and hyperten-
sion (HTN) [8]. Although infectious or immunosuppres-
sive drug-related causes are major aetiologies of death in
AAV patients, identifying predictors of all-cause mortal-
ity at diagnosis in immunosuppressive drug-naïve pa-
tients may have clinical implications in the real settings.
The fibrosis-4 index (FIB-4), which is calculated based
on age, aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and platelet count, was first
proposed to assess liver fibrosis in hepatitis C virus
(HCV)-monoinfected patients [9]. The critical cut-off of
FIB-4 for predicting significant liver fibrosis (S2 or
greater) is currently set as 1.45 [10]. Recently, it has
been reported that the baseline FIB-4 is significantly
associated with poor outcomes in patients with liver
diseases, such as hepatocellular carcinoma development
or all-cause mortality [11, 12]. FIB-4 was also reported
to be an independent risk factor of chronic kidney
disease in patients with non-alcoholic fatty liver disease
[13]. The association of FIB-4 with all-cause mortality
was also demonstrated in patients with heart failure,
which is a non-liver disease [14]. With this report, we
searched previous reports on the association between
the baseline FIB-4 and all-cause mortality in patients
with AAV. However, to our best knowledge, there was
no report regarding the association of FIB-4 at the time
of diagnosis of AAV with all-cause mortality during
follow-up to date. In our retrospective AAV-cohort, all-
cause mortality was observed only in patients with MPA
and GPA, but not EGPA [6]. Hence, in this study, we
investigated whether FIB-4 at diagnosis could be associ-
ated with all-cause mortality in 132 immunosuppressive
drug-naïve patients with MPA and GPA.
Methods
Patients
We retrospectively reviewed the medical records of 138
immunosuppressive drug-naïve patients with MPA and
GPA based on the following inclusion criteria: i) patients
who had been first classified as AAV at the Department
of Internal Medicine, Yonsei University College of
Medicine, Severance Hospital, from October 2000 to
December 2017; ii) patients who fulfilled the American
College of Rheumatology 1990 criteria and were reclassi-
fied by the 2007 European Medicines Agency algorithm,
in which authors added the modified contents of the
Chapel Hill Consensus Conferences (CHCC) Nomencla-
ture of Vasculitis proposed in 2012 [1, 2]; iii) patients
who had well-documented medical records with which
to assess both clinical manifestations at diagnosis and
death during follow-up, and calculate Birmingham vas-
culitis activity score (BVAS) and FFS (2009) at diagnosis
[15, 16]. Because BVAS for GPA has a different weight-
system compared to BVAS, we evenly applied BVAS to
GPA to unify the scoring system; iv) patients who had
results on perinuclear (P)-ANCA and cytoplasmic (C)-
ANCA or myeloperoxidase (MPO)-ANCA and protein-
ase 3 (PR3)-ANCA levels at diagnosis. v) patients who
had been followed up for 12 weeks or greater; vi) pa-
tients who had no medical history to affect either BVAS,
ANCA positivity or FIB-4 prior to or at diagnosis,
particularly, chronic liver diseases including viral
hepatitis, coexisting malignancies, serious comorbidities
and serious infection, which were identified in the 10th
revised International Classification Diseases; vii) patients
who had never received immunosuppressive drugs for
AAV prior to diagnosis, which were searched by the
Korean Drug Utilisation Review system. Of 138 AAV
patients, 2 patients were excluded due to HBsAg positive
and one patient was excluded due to anti-HCV positive.
And furthermore, 2 patients and one patient were ex-
cluded due to alcoholic liver disease and non-alcoholic
liver disease, respectively. Finally, we included 132 im-
munosuppressive drug-naïve patients with MPA (N = 91)
and GPA (N = 41).
Clinical and laboratory data
We obtained age at diagnosis and gender as demo-
graphic data and collected laboratory results including
ANCA at diagnosis as described in Table 1. BVAS and
FFS (2009) at diagnosis were calculated by reviewing the
medical records. Comorbidities belonging to BVAS or
FFS (2009), such as interstitial lung disease, diffuse
alveolar haemorrhage, gastrointestinal bleeding, cardio-
vascular diseases, chronic kidney disease ≥ stage 3 and
cerebrovascular accident, were excluded in AAV-related
risk factors for all-cause mortality. In this study, we
assessed old age (≥ 65 years), male gender, DM and
HTN at diagnosis as conventional risk factors, and GPA,
ANCA positivity at diagnosis, BVAS at diagnosis ≥16
and FFS (2009) at diagnosis ≥2 as AAV-related risk
factors for all-cause mortality during follow-up accord-
ing to the previous studies [6, 8]. We also evaluate the
predictive potential of FIB-4 at diagnosis ≥1.45 for
all-cause mortality for the follow-up period. We de-
fined the follow-up duration as the period from
diagnosis to the last visit in survived patients,
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whereas we defined it as the period from diagnosis to
death in deceased patients.
Equations of FIB-4 and significant liver fibrosis
FIB-4 = age (years) x AST (IU/L) / platelet count (109/
L)/√ALT (IU/L) [9]. The critical cut-off of FIB-4 for
significant liver fibrosis (S2–4) was set at 1.45 [10].
Statistical analyses
All statistical analyses were conducted using SPSS
software (version 23 for windows; IBM Corp., Armonk,
NY, USA). Continuous variables were expressed as a
mean ± standard deviation, and categorical variables
were expressed as a number (percentage). The multivari-
able Cox hazard model using variables with statistical
significance in the univariable Cox hazard model was
conducted to appropriately obtain the hazard ratios
(HRs) during the considerable follow-up duration. We
stratified AAV patients into three groups based on the
tertile of BVAS and defined the lower limit of the high-
est tertile as the cut-off for the current severe AAV
(BVAS at diagnosis ≥16). The odds ratio (OR) was
assessed using the multivariable logistic regression
analysis of variables with p-values less than 0.05 in the
univariable logistic regression analysis. P-values less than
0.05 were considered statistically significant.
Results
Baseline characteristics of 132 patients with MPA and GPA
The baseline characteristics were described in Table 1.
The mean age at diagnosis was 57.2 years and 40 pa-
tients (30.3%) were men. Ninety-one patients (68.9) were
classified as MPA and 41 patients (31.1%) were as GPA.
Any type of ANCA was detected in 112 patients (84.8%).
The mean BVAS and FFS (2009) at diagnosis were 13.1
and 1.4 and 57 patients (43.2%) had FFS (2009) at
diagnosis ≥2. The mean levels of AST and ALT at
diagnosis were 23.2 IU/L and 23.4 IU/L, and the mean
platelet count at diagnosis was 331,800.0/mm3. The
mean FIB-4 at diagnosis was 1.1 and 27 patients (20.5%)
had significant liver fibrosis (FIB-4 ≥ 1.45). At diagnosis,
26 patients (19.7%) had DM and 61 patients (46.2%) had
HTN. The mean follow-up duration was 52.4 months
and 15 patients (11.4%) died. During follow-up,
glucocorticoid was the most frequently administered
drug (84.8%), followed by cyclophosphamide (43.2%) and
azathioprine (24.2%).
Univariable cox hazards model analysis of risk factors for
all-cause mortality
Among conventional risk factors for all-cause mortality,
age at diagnosis ≥65 years (HR 5.055, 95% confidence
interval 1.593, 16.039), DM at diagnosis (HR 3.446, 95%
CI 1.111, 10.692) and HTN at diagnosis (HR 4.611, 95%
Table 1 Baseline characteristics of patients with MPA and GPA
(N = 132)
Variables Values
Demographic data
Age at diagnosis (year old) 57.2 ± 14.7
Male gender (N, (%)) 40 (30.3)
AAV variants (N, (%))
MPA 91 (68.9)
GPA 41 (31.1)
ANCA positivity (N, (%)) 112 (84.8)
Activity and prognostic factor at diagnosis
BVAS 13.1 ± 7.2
FFS (2009) 1.4 ± 1.0
FFS (2009)≥ 2 (N, (%)) 57 (43.2)
Laboratory results at diagnosis
White blood cell (/mm3) 9538.3 ± 3940.5
Haemoglobin (g/dL) 12.0 ± 1.2
Platelet × 103 (/mm3) 331.8 ± 144.7
Prothrombin time (INR) 1.0 ± 0.1
Fasting glucose (mg/dL) 116.8 ± 44.6
Blood urea nitrogen (mg/dL) 28.1 ± 25.3
Creatinine (mg/dL) 1.9 ± 2.1
Protein (g/dL) 6.7 ± 0.9
Serum albumin (g/dL) 3.5 ± 0.8
Alkaline phosphatase (IU/L) 93.7 ± 94.3
Aspartate aminotransferase (IU/L) 23.2 ± 26.5
Alanine aminotransferase (IU/L) 23.4 ± 39.3
Total bilirubin (mg/dL) 0.7 ± 1.6
Total cholesterol (mg/dL) 171.4 ± 50.4
Acute reactants at diagnosis
Erythrocyte sedimentation rate (mm/hr) 62.8 ± 38.0
C-reactive protein (mg/L) 44.0 ± 56.8
Liver fibrosis index at diagnosis
FIB-4 1.1 ± 0.9
FIB-4≥ 1.45 (N, (%)) 27 (20.5)
Comorbidities except items of BVAS or FFS (2009) at diagnosisa (N, (%))
DM 26 (19.7)
HTN 61 (46.2)
Follow-up duration (months) 52.4 ± 52.2
Death (N, (%)) 15 (11.4%)
Values are expressed as a mean ± standard deviation and number (N) (%)
a interstitial lung disease, diffuse alveolar haemorrhage, gastrointestinal
bleeding, cardiovascular diseases, chronic kidney disease ≥ stage 3 and
cerebrovascular accident and so on
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic antibody,
MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, BVAS
Birmingham vasculitis activity score, FFS five factor score, FIB-4 fibrosis-4,
DM diabetes mellitus, HTN hypertension
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CI 1.016, 20.927) were significantly associated with all-
cause mortality Among AAV-related risk factor for all-
cause mortality, only FFS (2009) at diagnosis ≥2 (HR
4.849, 95% CI 1.341, 17.537) was significantly associated
with all-cause mortality. In addition, FIB-4 at diagnosis
≥1.45 (HR 9.958, 95% CI 2.550, 38.877) also exhibited a
significant association with all-cause mortality during
follow-up in patients with MPA and GPA (Table 2).
Multivariable cox hazards model analysis of risk factors
for all-cause mortality
We also conducted the multivariable Cox hazards model
using variables with statistical significance in the univari-
able Cox hazards model. Among age ≥ 65 years, DM,
HTN, FFS (2009) ≥ 2 and FIB-4 ≥ 1.45 at diagnosis, only
FIB-4 at diagnosis ≥1.45 was an independent predictor
of all-cause mortality during the follow-up in patients
with MPA and GPA (Table 3).
Discussion
In this study, we compared the predictive potential of
FIB-4 at diagnosis ≥1.45 with those of conventional and
AAV-related risk factors for all-cause mortality in 132
immunosuppressive drug-naïve patients with MPA and
GPA. In the multivariable Cox Hazard model analysis,
old age (≥ 65 years), DM, HTN, FFS (2009) ≥ 2 and FIB-
4 ≥ 1.45 at diagnosis were included. Interestingly, we
found that only FIB-4 at diagnosis ≥1.45 was associated
with all-cause mortality during follow-up in patients
MPA and GPA. We considered two reasons why FIB-
4 ≥ 1.45 at diagnosis exhibited the relatively high predict-
ive power for all-cause mortality. First, inflammation
may accelerate systemic fibrotic change through various
inflammatory signals. Thus, the extent of liver fibrosis
may indirectly reflect the accumulated amount of
inflammatory burden in non-liver diseases such as heart
failure [14]. We assume that FIB-4 at diagnosis could
predict all-cause mortality in MPA and GPA patients in
a similar manner. Next, we assume that FIB-4 might be
influenced by both conventional and AAV-related risk
factors for all-cause mortality prior to or at the time of
diagnosis. To prove this assumption, we conducted the
univariable and multivariable logistic regression analysis
based on FIB-4 at diagnosis ≥1.45 using those risk
factors at diagnosis. In the univariable analysis, age at
diagnosis ≥65 years (OR 3.812) and DM at diagnosis
(OR 5.200) were significantly associated with FIB-4 at
diagnosis ≥1.45. BVAS at diagnosis ≥16 and FFS (2009)
at diagnosis ≥2 exhibited a tendency to be associated
with FIB-4, so they were also included in the multivari-
able analysis. In the multivariable analysis, only age at
diagnosis ≥65 years (OR 3.088, 95% CI 1.157, 8.239) and
DM at diagnosis (OR 4.556, 95% CI 1.678, 12.368) were
significantly associated with FIB-4 at diagnosis ≥1.45
(Additional file 1: Table S1).
Since, age is one of variables comprising an equation
of FIB-4, it is naturally accepted that FIB-4 may be dir-
ectly correlated with age [9]. Whereas, pre-existing DM
could induce non-alcoholic fatty liver disease, one of the
systemic complication of DM, which can lead to an in-
crease in FIB-4 within 3 years from baseline [17, 18].
The link between male gender and FIB-4 is contro-
versial: according to a previous review regarding an
effect of gender on the outcome of liver diseases,
differences in incidence and severity of liver diseases
between men and women may vary based on a
disease-type [19]. The relation between pre-existing
systemic HTN and FIB-4 is also controversial: non-
alcoholic fatty liver disease was identified as an inde-
pendent risk factor for the development of systemic
HTN [20]. Therefore, we conclude that FIB-4 at
diagnosis itself may be an independent predictor of
all-cause mortality in MPA and GPA patients and at
Table 2 Univariable Cox Hazards model analysis of conventional
and AAV-related risk factors for all-cause mortality in patients with
MPA and GPA
Variables HR 95% confidence
interval
P-value
Age at diagnosis ≥65 years 5.055 1.593, 16.039 0.006
Male gender 0.557 0.195, 1.587 0.273
DM at diagnosis 3.446 1.111, 10.692 0.032
HTN at diagnosis 4.611 1.016, 20.927 0.048
GPA versus MPA 1.002 0.311, 3.226 0.997
ANCA positivity at diagnosis 3.423 0759, 15.438 0.109
BVAS at diagnosis ≥16 1.554 0.553, 4.370 0.403
FFS (2009) at diagnosis ≥2 4.849 1.341, 17.537 0.016
FIB-4 at diagnosis ≥1.45 9.958 2.550, 38.877 0.001
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic antibody,
GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, BVAS
Birmingham vasculitis activity score, FFS five factor score, FIB-4 fibrosis-4, DM
diabetes mellitus, HTN hypertension
Table 3 Multivariable Cox Hazards model analysis of conventional
and AAV-related risk factors for all-cause mortality in patients with
MPA and GPA
Variables Including age at diagnosis≥ 65 years
HR 95% confidence
interval
P-value
Age at diagnosis ≥65 years 2.491 0.656, 9.459 0.180
DM at diagnosis 1.581 0.426, 5.864 0.493
HTN at diagnosis 1.727 0.332, 8.987 0.516
FFS (2009) at diagnosis ≥2 2.921 0.705, 12.095 0.139
FIB-4 at diagnosis ≥1.45 6.253 1.398, 27.963 0.016
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic antibody,
GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, BVAS
Birmingham vasculitis activity score, FFS five factor score, FIB-4 fibrosis-4, DM
diabetes mellitus, HTN hypertension
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the same time, it may reflect the effect of old age and
DM on subclinical liver fibrosis, leading to an in-
crease in FIB-4 at diagnosis.
Despite no significant association in the multivariable
logistic regression analysis, BVAS and FFS (2009) at
diagnosis exhibited a tendency to be associated with
FIB-4 at diagnosis. In cases of severe MPA and GPA, as
a counterpart of TH1 and TH17 cells, which are import-
ant participants in the pathogenesis of AAV, Treg cells
may enhance the production of transforming growth
factors (TGF)-β, which can initiate and accelerate liver
fibrosis [21]. Moreover, the higher extent of inflamma-
tory burden may provoke the augmented production of
reactive oxygen species, which can subsequently pro-
mote cell differentiation of fibroblasts to myoblasts in
liver [22]. Since BVAS and FFS (2009) were calculated at
diagnosis of MPA and GPA, together with FIB-4 at diag-
nosis, the effect of BVAS and FFS (2009) at diagnosis on
FIB-4 at diagnosis might be negligible. However, consid-
ering an asymptomatic latency prior to diagnosis of
MPA and GPA, BVAS and FFS (2009) at diagnosis might
theoretically influence FIB-4 at diagnosis. Therefore, we
also conclude that FIB-4 at diagnosis may reflect the
subtle effect of the inflammatory burden of AAV on sub-
clinical liver fibrosis, leading to an increase in FIB-4 at
diagnosis.
In addition to conventional and AAV-related risk
factors, we investigated the predictive potential of co-
morbidities at diagnosis for all-cause mortality. Intersti-
tial lung disease at diagnosis (HR 6.981, 95% CI 1.535,
31.756) was significantly associated with all-cause
mortality in MPA and GPA patients. However, chronic
kidney disease over stage 3 (HR 2.615, 95% CI 0.883,
7.742), ischaemic heart disease (HR 3.493, 95% 0.703,
17.361) and cerebrovascular disease (HR 1.213, 95% CI
0.324, 4.546) at diagnosis exhibited no significant associ-
ation with all-cause mortality. We added interstitial lung
disease at diagnosis to the multivariable Cox Hazards
model analysis together with 5 variables described in
Table 3. Nevertheless, only FIB-4 at diagnosis ≥1.45 was
significantly associated with all-cause mortality. Because
interstitial lung disease is not an established conven-
tional or AAV-related risk factor for all-cause mortality,
we did not include interstitial lung disease in the multi-
variable Cox Hazards model in this study.
In this study, we first demonstrated that FIB-4 at
diagnosis ≥1.45 is an independent predictor of all-cause
mortality during follow-up in patients with MPA and
GPA, and furthermore its predictive potential is higher
than those of conventional and AAV-related risk factors
for all-cause mortality. However, our study also has
several issues. First, despite the significant association
between FIB-4 at diagnosis and all-cause mortality, we
could not clarify the direct mechanism of FIB-4 at
diagnosis to estimate all-cause mortality. Second, we
could not provide the concrete data on liver fibrosis by
liver histology or transient elastography. Third, our study
was designed as a retrospective study, we could not
strictly control the confounding factors. Particularly, we
could not confirm the repeated results of ANCAs in pa-
tients without ANCA. Fourth, this study was conducted
in a single centre, the number of deceased patients was
too small to augment the statistical power. Future pro-
spective and multi-centric studies with a larger number
of patients will validate the clinical significance of FIB-4
at diagnosis in predicting all-cause mortality during
follow-up of MPA and GPA in real-world clinical
practice.
Conclusions
FIB-4 at diagnosis ≥1.45 is an independent predictor of
all-cause mortality during follow-up in patients with
MPA and GPA, and furthermore its predictive potential
is higher than those of conventional and AAV-related
risk factors for all-cause mortality.
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